Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Canada-based nanomedicines producer Precision NanoSystems has entered into an agreement with Arcturus Therapeutics to develop new ribonucleic acid (RNA) medicines.
Subscribe to our email newsletter
As part of the deal, Precision’s NanoAssemblr platform will be used to manufacture GMP batches to support clinical trials and commercial development for RNA medicines developed using Arcturus’ LUNAR RNA Therapeutics platform.
Precision CEO James Taylor said: ""We have been working very closely with Arcturus during the discovery phase of the LUNAR products and we are excited to support ongoing development through clinical manufacture using our NanoAssemblr microfluidics-based platform for the manufacture of nanomedicines."
The partnership is expected to accelerate clinical development and allow Arcturus to effectively formulate its LUNAR nanoparticles.
Arcturus is a small interfering RNA (siRNA) and messenger RNA (mRNA) drug discovery and development company.